Small Cell Lung Cancer Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

An Open-label, Multicenter Study of ZL-1310 in Subjects With Small Cell Lung Cancer
Conditions: SCLC Interventions: Drug: ZL-1310 Sponsors: Zai Lab (Shanghai) Co., Ltd.; Zai Lab (US) LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 21, 2023 Category: Research Source Type: clinical trials

A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC
Conditions: Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Small Cell Lung Carcinoma Interventions: Drug: Adebrelimab; Drug: Carboplatin/Cisplatin; Drug: Etoposide; Radiation: Radiation therapy Sponsors: Nanfang Hospital, Southern Medical University; Suzhou Suncadia Biopharmaceuticals Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 20, 2023 Category: Research Source Type: clinical trials

Adebelizumab Combined With Chemotherapy and Radiotherapy Treat ES-SCLC
Conditions: Extensive Small Cell Lung Cancer Interventions: Drug: Adebelizumab+Carboplatin+Etoposide+Concurrent Radiotherapy Sponsors: Qianfoshan Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 9, 2023 Category: Research Source Type: clinical trials

Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
Conditions: Limited Stage Small Cell Lung Cancer; Small Cell Lung Cancer Interventions: Drug: Tarlatamab; Drug: Placebo Sponsors: Amgen Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 6, 2023 Category: Research Source Type: clinical trials

Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS)
Conditions: Prostate Cancer; Head and Neck Cancer; NSCLC; SCLC; Esophageal Cancer; Bladder Cancer; Rectum Cancer; Cervix Cancer; Other Carcinoma Interventions: Radiation: Online adaptive radiation therapy Sponsors: Charite University, Berlin, Germany Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 3, 2023 Category: Research Source Type: clinical trials

Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation
Conditions: Extensive Stage Lung Small Cell Carcinoma; Stage IV Lung Cancer Interventions: Drug: Carboplatin; Biological: Atezolizumab; Drug: Etoposide; Radiation: Total Body Irradiation; Radiation: Hypofractionated Radiation Therapy; Procedure: Magnetic Resonance Imaging Sponsors: Vanderbilt-Ingram Cancer Center; Genentech, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 31, 2023 Category: Research Source Type: clinical trials

A Study to Assess Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
Conditions: Limited-stage Small Cell Lung Cancer (LS-SCLC) Interventions: Drug: Tifcemalimab injection; Drug: toripalimab injection; Drug: Placebo for Tifcemalimab; Drug: Placebo for toripalimab Sponsors: Shanghai Junshi Bioscience Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 23, 2023 Category: Research Source Type: clinical trials

Amgen Presents New Tarlatamab Data In Small Cell Lung Cancer
Tarlatamab Delivered an Encouraging Objective Response Rate of 40% and Median Overall Survival of 14.3 Months in Patients with Advanced SCLC Late-Breaking Data Presented at ESMO and Published in the New England Journal of Medicine... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 20, 2023 Category: Pharmaceuticals Source Type: clinical trials

DAREON ᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer
Conditions: Small Cell Lung Carcinoma (SCLC) Interventions: Drug: BI 764532; Drug: Carboplatin; Drug: Etoposide; Drug: Atezolizumab; Drug: Durvalumab; Drug: Cisplatin Sponsors: Boehringer Ingelheim Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 11, 2023 Category: Research Source Type: clinical trials

ARTEMIS-007: HS-20093 in Patients With Extensive Stage Small Cell Lung Cancer
Condition: Extensive Stage Small Cell Lung Cancer (ES-SCLC) Intervention: Drug: HS-20093 Sponsor: Hansoh BioMedical R&D Company Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 25, 2023 Category: Research Source Type: clinical trials

ARTEMIS-007: HS-20093 in Patients With Extensive Stage Small Cell Lung Cancer
Conditions: Extensive Stage Small Cell Lung Cancer (ES-SCLC) Interventions: Drug: HS-20093 Sponsors: Hansoh BioMedical R&D Company Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 25, 2023 Category: Research Source Type: clinical trials

IN10018 Combination Therapy in Treatment-na ïve ES-SCLC
Condition: Small Cell Lung Cancer Extensive Stage Interventions: Drug: IN10018; Drug: Tislelizumab; Drug: Carboplatin; Drug: Etoposide Sponsor: InxMed (Shanghai) Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 8, 2023 Category: Research Source Type: clinical trials